CXC chemokines: The regulatory link between inflammation and angiogenesis

Trends in Immunology

Volumn 25, Issue 4, 2004, Pages 201-209

  Romagnani, Paola ^a   Lasagni, Laura ^a   Annunziato, Francesco ^a   Serio, Mario ^a   Romagnani, Sergio ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CXC10; CHEMOKINE RECEPTOR CXC11; CHEMOKINE RECEPTOR CXCL1; CHEMOKINE RECEPTOR CXCL3; CHEMOKINE RECEPTOR CXCL4; CHEMOKINE RECEPTOR CXCL5; CHEMOKINE RECEPTOR CXCL7; CHEMOKINE RECEPTOR CXCL9; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; INTERLEUKIN 8; UNCLASSIFIED DRUG; VASCULOTROPIN A; VON HIPPEL LINDAU PROTEIN;

ANGIOGENESIS; CARCINOGENESIS; CARCINOGENICITY; ENDOTHELIUM CELL; GENE ACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; HEAD AND NECK CANCER; IMMUNOSURVEILLANCE; INFLAMMATION; KAPOSI SARCOMA; KIDNEY CARCINOMA; LEUKOCYTE; MELANOMA CELL; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PANCREAS CANCER; PHAGOCYTOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TISSUE REPAIR; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ANGIOGENESIS MODULATING AGENTS; ANIMALS; CHEMOKINES, CXC; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, CHEMOKINE; WOUND HEALING;

EID: 1642274574     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2004.02.006     Document Type: Review

References (84)

1. Zlotnik A., Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity. 12:2000;121-127.
2. Rossi D., Zlotnik A. The biology of chemokines and their receptors. Annu. Rev. Immunol. 18:2000;217-242.
3. + progenitors to peripheral blood. J. Exp. Med. 185:1997;111-120.
4. Strieter R.M., et al. CXC chemokines in angiogenesis related to pulmonary fibrosis. Chest. 122:2002;298S-301S.
5. Yoshie O., et al. Chemokines in immunity. Adv. Immunol. 78:2001;57-110.
6. Huising M.O., et al. Molecular evolution of CXC chemokines: extant CXC chemokines originate from the CNS. Trends Immunol. 24:2003;306-313.
7. Salcedo R., Oppenheim J.J. Role of chemokines in angiogenesis: CXCL12/SDF-1 and CXCR4 interaction, a key regulator of endothelial cell responses. Microcirculation. 10:2003;359-370.
8. Bernardini G., et al. Analysis of the role of chemokines in angiogenesis. J. Immunol. Methods. 273:2003;83-101.
9. Tachibana K., et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature. 393:1998;591-594.
10. Nagasawa T., et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature. 382:1996;635-638.
11. Le Couter J., et al. Identification of an angiogenic mitogen selective for endocrine gland endothelium. Nature. 412:2001;877-884.
12. Salcedo R., et al. Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: in vivo neovascularization induced by stromal-derived factor-1α Am. J. Pathol. 154:1999;1125-1135.
13. Staller P., et al. Chemokine receptor CXCR4 downregulated by Von Hippel-Lindau tumor suppressor pVHL. Nature. 425:2003;307-311.
14. +CXC chemokine-induced angiogenic activity. J. Immunol. 165:2000;5269-5277.
15. Sgadari C., et al. Mig, the monokine induced by interferon-γ, promotes tumor necrosis in vivo. Blood. 89:1997;2635-2643.
16. Feil C., Augustin H.G. Endothelial cells differentially express functional CXC-chemokine receptor-4 (CXCR-4/fusin) under the control of autocrine activity and exogenous cytokines. Biochem. Biophys. Res. Commun. 247:1998;38-45.
17. Volin M.V., et al. Chemokine receptor CXCR4 expression in endothelium. Biochem. Biophys. Res. Commun. 242:1998;46-53.
18. Vicari A.P., et al. Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms. J. Immunol. 165:2000;1992-2000.
19. Salcedo R., et al. Differential expression and responsiveness of chemokine receptors (CXCR1-3) by human microvascular endothelial cells and umbilical vein endothelial cells. FASEB J. 14:2000;2055-2064.
20. Romagnani P., et al. Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. J. Clin. Invest. 107:2001;53-63.
21. Zwicker J., et al. Cell cycle regulation of the cyclin A, cdc25C and cdc2 genes is based on a common mechanism of transcriptional repression. EMBO J. 14:1995;4514-4522.
22. Goldberg S.H., et al. CXCR3 expression in human central nervous system diseases. Neuropathol. Appl. Neurobiol. 27:2001;127-138.
23. Van Der Meer P., et al. Expression pattern of CXCR3, CXCR4, and CCR3 chemokine receptors in the developing human brain. J. Neuropathol. Exp. Neurol. 60:2001;25-32.
24. Luster A.D., et al. The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. J. Exp. Med. 182:1995;219-231.
25. Proost P., et al. Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. Blood. 98:2001;3554-3561.
26. Hansell P., et al. Selective binding of platelet factor 4 to regions of active angiogenesis in vivo. Am. J. Physiol. 269:1995;H829-H836.
27. Zucker M.B., Katz I.R. Platelet factor 4: production, structure, and physiologic and immunologic action. Proc. Soc. Exp. Biol. Med. 198:1991;693-702.
28. Jenh C.H., et al. Human B cell-attracting chemokine 1 (BCA-1; CXCL13) is an agonist for the human CXCR3 receptor. Cytokine. 15:2001;113-121.
29. Loetscher M., et al. Chemokine receptor specific for IP10 and Mig: structure, function, and expression in activated T-lymphocytes. J. Exp. Med. 184:1996;963-969.
30. Romagnani P., et al. Role for interactions between IP-10/Mig and their receptor (CXCR3) in proliferative glomerulonephritis. J. Am. Soc. Nephrol. 10:1999;2518-2526.
31. Romagnani P., et al. IP-10 and Mig production by glomerular cells in human proliferative glomerulonephritis and regulation by nitric oxide. J. Am. Soc. Nephrol. 13:2002;53-64.
32. Zhao D.X., et al. Differential expression of the IFN-γ-inducible CXCR3-binding chemokines, IFN-inducible protein 10, monokine induced by IFN, and IFN-inducible T cell α chemoattractant in human cardiac allografts: association with cardiac allograft vasculopathy and acute rejection. J. Immunol. 169:2002;1556-1560.
33. Wang X., et al. Interferon-inducible protein-10 involves vascular smooth muscle cell migration, proliferation, and inflammatory response. J. Biol. Chem. 271:1996;24286-24293.
34. Bonacchi A., et al. Signal transduction by the chemokine receptor CXCR3: activation of Ras/ERK, Src, and phosphatidylinositol 3-kinase/Akt controls cell migration and proliferation in human vascular pericytes. J. Biol. Chem. 276:2001;9945-9954.
35. Lasagni L., et al. An alternatively spliced variant of CXCR3 mediates the IP-10, Mig and I-TAC induced-inhibition of endothelial cell growth and acts as functional receptor for PF-4. J. Exp. Med. 197:2003;1537-1549.
36. Spinetti G., et al. The chemokine CXCL13 (BCA-1) inhibits FGF-2 effects on endothelial cells. Biochem. Biophys. Res. Commun. 289:2001;19-24.
37. Griffioen A.W., Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol. Rev. 52:2000;237-268.
38. Werner S., Grose R. Regulation of wound healing by growth factors and cytokines. Physiol. Rev. 83:2003;835-870.
39. Gillitzer R., Goebeler M. Chemokines in cutaneous wound healing. J. Leukoc. Biol. 69:2001;513-521.
40. Shuman M.A., Levine S.P. Thrombin generation and secretion of platelet factor 4 during blood clotting. J. Clin. Invest. 61:1978;1102-1106.
41. Engelhardt E., et al. Chemokines IL-8, GROα, MCP-1, IP-10, and Mig are sequentially and differentially expressed during phase-specific infiltration of leukocyte subsets in human wound healing. Am. J. Pathol. 153:1998;1849-1860.
42. Kemeny L., et al. Role of interleukin-8 receptor in skin. Int. Arch. Allergy Immunol. 104:1994;317-322.
43. Devalaraja R.M., et al. Delayed wound healing in CXCR2 knockout mice. J. Invest. Dermatol. 115:2000;234-244.
44. Dipietro L.A., et al. Modulation of macrophage recruitment into wounds by monocyte chemoattractant protein-1. Wound Repair Regen. 9:2001;28-33.
45. Fedyk E.R., et al. Expression of stromal-derived factor-1 is decreased by IL-1 and TNF in dermal wound healing. J. Immunol. 166:2001;5749-5755.
46. Satish L., et al. Glu-Leu-Arg-negative CXC chemokine interferon-γ inducible protein-9 as a mediator of epidermal-dermal communication during wound repair. J. Invest. Dermatol. 120:2003;1110-1117.
47. Rennekampf H.O., et al. Bioactive interleukin-8 is expressed in wounds and enhances wound healing. J. Surg. Res. 93:2000;41-54.
48. Iocono J.A., et al. Interleukin-8 levels and activity in delayed-healing human thermal wounds. Wound Repair Regen. 8:2000;216-225.
49. Shiraha H., et al. IP-10 inhibits epidermal growth factor-induced motility by decreasing epidermal growth factor receptor-mediated calpain activity. J. Cell Biol. 146:1999;243-254.
50. Coussens L.M., Werb Z. Inflammation and cancer. Nature. 420:2002;860-867.
51. Bonecchi R., et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J. Exp. Med. 187:1998;129-134.
52. + T cells, and natural killer-type cells in human thymus. Blood. 97:2001;601-607.
53. Janatpour M.J., et al. Tumor necrosis factor-dependent segmental control of MIG expression by high endothelial venules in inflamed lymph nodes regulates monocyte recruitment. J. Exp. Med. 194:2001;1375-1384.
54. Penna G., et al. Cutting edge: selective usage of chemokine receptors by plasmacytoid dendritic cells. J. Immunol. 167:2001;1862-1866.
55. Luster A.D., Leder P. IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo. J. Exp. Med. 178:1993;1057-1065.
56. Yao L., et al. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood. 93:1999;1612-1621.
57. Tannenbaum C.S., et al. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J. Immunol. 161:1998;927-932.
58. Kanegane C., et al. Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12. J. Leukoc. Biol. 64:1998;384-392.
59. Nastala C.L., et al. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J. Immunol. 153:1994;1697-1706.
60. Brunda M.J., et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 178:1993;1223-1230.
61. + αβT cells activated by IL-12 as a major effector in inhibition of experimental tumor metastasis. J. Immunol. 156:1996;3366-3373.
62. Sgadari C., et al. Inhibition of angiogenesis by interleukin-12 is mediated by interferon-inducible protein 10. Blood. 87:1996;3877-3882.
63. Bergers G., Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer. 3:2003;401-410.
64. Rofstad E.K., et al. Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts. Cancer Res. 60:2000;4932-4938.
65. Desbaillets I., et al. Upregulation of interleukin 8 by oxygen-deprived cells in glioblastoma suggests a role in leukocyte activation, chemotaxis, and angiogenesis. J. Exp. Med. 186:1997;1201-1212.
66. Lane B.R., et al. Interleukin-8 and growth-regulated oncogene α mediate angiogenesis in Kaposi's sarcoma. J. Virol. 76:2002;11570-11583.
67. Yamaguchi J., et al. Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation. 107:2003;1322-1328.
68. Tanaka T., et al. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nat. Med. 3:1997;437-442.
69. Homey B., et al. Chemokines: agents for the immunotherapy of cancer? Nat. Rev. Immunol. 2:2002;175-184.
70. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 100:2000;57-70.
71. Muller A., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 410:2001;50-56.
72. Vicari A.P., Caux C. Chemokines in cancer. Cytokine Growth Factor Rev. 13:2002;143-154.
73. Farrow B., Evers B.M. Inflammation and the development of pancreatic cancer. Surg. Oncol. 10:2002;153-169.
74. Arenberg D.A., et al. Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer. J. Clin. Invest. 102:1998;465-472.
75. Norgauer J., et al. Expression and growth-promoting function of the IL-8 receptor β in human melanoma cells. J. Immunol. 156:1996;1132-1137.
76. Balentien E., et al. Effects of MGSA/GROα on melanocyte transformation. Oncogene. 6:1991;1115-1124.
77. Owen J.D., et al. Enhanced tumor-forming capacity for immortalized melanocytes expressing melanoma growth stimulatory activity/growth-regulated cytokine β and γ proteins. Int. J. Cancer. 73:1997;94-103.
78. Tatakis D.N. Human platelet factor 4 is a direct inhibitor of human osteoblast-like osteosarcoma cell growth. Biochem. Biophys. Res. Commun. 187:1992;287-293.
79. Sulpice E., et al. Platelet factor 4 inhibits FGF2-induced endothelial cell proliferation via the extracellular signal-regulated kinase pathway but not by the phosphatidylinositol 3-kinase pathway. Blood. 100:2002;3087-3094.
80. Cip1/WAF1. Blood. 93:1999;25-33.
81. 165 using several concurrent mechanisms. J. Biol. Chem. 270:1995;15059-15065.
82. Maione T.E., et al. Inhibition of tumor growth in mice by an analogue of platelet factor 4 that lacks affinity for heparin and retains potent angiostatic activity. Cancer Res. 51:1991;2077-2083.
83. Shiraha H., et al. IP-10 inhibits epidermal growth factor-induced motility by decreasing epidermal growth factor receptor-mediated calpain activity. J. Cell Biol. 146:1999;243-254.
84. Jouan V., et al. Inhibition of in vitro angiogenesis by platelet factor-4-derived peptides and mechanism of action. Blood. 94:1999;984-993.